Anatomic shoulder replacement holds at 15 years, colchicine fails in knee osteoarthritis, and shockwave helps some tendons more than others

The edition in brief

A retrospective cohort of 791 anatomic total shoulder arthroplasties reported implant survivorship of 96.1% at ten years and 93.7% at fifteen, with Walch B glenoid morphology and younger age linked to revision. At ten years 79.9% of shoulders met the minimal clinically important difference on the ASES score and 55.8% the substantial clinical benefit threshold, though function attenuated gradually. In CLOAK, 120 people with knee osteoarthritis randomised to colchicine or placebo for three months showed no difference in pain, function or effusion size, despite improvements in some inflammatory biomarkers. A phase 2 trial of 120 patients found intravenous lidocaine did not significantly reduce rebound pain after interscalene block for rotator cuff repair (23.3% versus 36.7%, relative risk 0.64, 95% CI 0.36 to 1.12), though the trial was probably underpowered. A registry-based projection estimates revision hip and knee arthroplasty volumes in 17 countries will rise about 36% by 2060. A network meta-analysis of 65 trials suggests shockwave therapy improves pain in several tendinopathies but showed no significant effect over placebo in patellar tendinopathy.